Platelet aggregation in midlife was associated with PET and MRI markers of Alzheimer disease pathology, consistent with a neurodegenerative pattern (P<0.035).
Observational
Is platelet aggregation in midlife associated with imaging markers of Alzheimer disease pathology in dementia-free middle-aged adults?
Platelet aggregation in midlife is associated with early PET and MRI imaging markers of Alzheimer's disease pathology, suggesting a potential role for platelet-mediated mechanisms in AD pathogenesis.
p-value: p=<0.035
BACKGROUND AND OBJECTIVES: Vascular dysfunction contributes to Alzheimer disease (AD) and related dementias (ADRDs), but the underlying mechanisms remain unclear. Previous studies link midlife hemostasis and platelet aggregation measures to late-life dementia risk. We aimed to determine whether platelet aggregation in midlife is associated with imaging markers of AD pathology. METHODS: F-flortaucipir) PET uptake in dementia-free, middle-aged adults from the Framingham Heart Study. Co-primary outcomes included amyloid and tau uptake in AD-vulnerable regions. We also examined an MRI-based cortical thickness signature of AD risk as a secondary outcome. We used multivariable regression models adjusted for demographic and clinical factors, considering potential nonlinear associations. RESULTS: < 0.035), consistent with a neurodegenerative pattern. DISCUSSION: Our findings indicate that platelet aggregation is linked to PET and MRI markers of AD pathology as early as midlife. These findings support further investigation of platelet-mediated mechanisms in AD pathogenesis.
Ramos‐Cejudo et al. (Tue,) conducted a observational in Alzheimer disease pathology. Platelet aggregation was evaluated on Amyloid and tau uptake in AD-vulnerable regions (p=<0.035). Platelet aggregation in midlife was associated with PET and MRI markers of Alzheimer disease pathology, consistent with a neurodegenerative pattern (P<0.035).